Outpatient based colorectal cancer treatment--the current status, challenges and future outlook
Kimura, H.; Akazai, Y.; Nitta, Y.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(5): 606-610
2006
ISSN/ISBN: 0385-0684 PMID: 16685157 Document Number: 604531
In recent years, chemotherapy for colorectal cancer has advanced rapidly. It has taken on the primary role in the treatment of advanced/metastatic colorectal cancer. However, surgery and radiation therapy continue to be integral measures in managing the various symptoms which occur during chemotherapy. The objective in treating non-resectable recurrent colorectal cancer is to maintain excellent QOL, while attempting to prolong the patient's life. Currently,the standard treatment in our nation is FOLFIRI/FOLFOX; however, the Western nations are starting to implement molecular targeted agents, although extremely costly. High expectations are held for research efforts oriented towards the effectiveness of oral fluoropyrimidines, anti-cancer drug sensitivity and the prognosis for side effects. It is requisite to maintain balance between QOL and life prolongation. In order to achieve this, it is imperative to listen closely to what the patient is feeling, and to continue providing support to alleviate the patient's uncertainties and troubles. Knowledge of palliative medicine and active listening methodology become necessary for the medical professional. EBM should not be the only focus; the thinking of each individual should be respected, and outpatient-based chemotherapy should be attempted, allowing the individual to maintain everyday living and social activities. One looks forward to the fruition of customized medicine which corresponds to the "nature of cancer "with the "patient's individuality."